Calmerry vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Subscription online therapy via text, video, and audio; accessible pricing for patients managing anxiety and depression; therapist matching with easy switching based on preference selection.
About
Calmerry is an online therapy platform that connects individuals with licensed therapists for mental health support through a subscription model covering text messaging, live video sessions, and audio calls. The platform focuses on accessibility and affordability, offering therapy to users who face barriers of cost, stigma, or geographic access to traditional in-person care. Calmerry matches clients to therapists based on their presenting concerns, preferences, and therapist specialization, with the ability to switch therapists if the initial match is not a good fit. The platform serves a primarily direct-to-consumer audience, individuals managing anxiety, depression, relationship issues, stress, and other mental health concerns. Calmerry competes with BetterHelp and Talkspace in the online therapy market, differentiating through competitive pricing and a straightforward subscription structure. The company has grown rapidly as awareness of teletherapy has expanded following the COVID-19 pandemic, which accelerated consumer acceptance of remote mental healthcare.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.